Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib versus investigator's choice single-agent therapy in relapsed or refractory peripheral T-cell lymphoma
NL-OMON39884Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of alisertib in peripheral T-cell lymphoma (PTCL) (2 arms), sponsored by Takeda. Primary endpoints: Overall response rate and Progression-free survival. Started Jul 2013; status: active, not recruiting.
02
Drugs
alisertib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NL-OMON39884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39884.